Lupin Launches Authorized Generic Version of Antara® in the United States

Global pharma major Lupin Limited (Lupin) announced the launch of the authorized generic version of Antara® (Fenofibrate) Capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, S.A. Corporation, a wholly-owned subsidiary of Lupin.

Fenofibrate Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides rrG) and apolopoprotein B (Apo B), and to increase high-density fipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.

Fenofibrate Capsules (RLD: Antara® Capsules) had estimated annual sales of USD 7 million in the U.S. (IQVIA MAT September 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 933.95 as compared to the previous close of Rs. 934.75. The total number of shares traded during the day was 4615 in over 352 trades.

The stock hit an intraday high of Rs. 941.50 and intraday low of 932.30. The net turnover during the day was Rs. 4317676.00.

Source : Equity Bulls

Keywords

LupinLimited INE326A01037 Pharmaceuticals AntaraCapsules GenericVersion